PMID- 27916496
OWN - NLM
STAT- MEDLINE
DCOM- 20170209
LR  - 20171017
IS  - 2352-3840 (Electronic)
IS  - 1499-2671 (Linking)
VI  - 41
IP  - 1
DP  - 2017 Feb
TI  - Hyperlipidemia-Mediated Increased Advanced Lipoxidation End Products Formation, 
      an Important Factor Associated with Decreased Erythrocyte Glucose-6-Phosphate 
      Dehydrogenase Activity in Mild Nonproliferative Diabetic Retinopathy.
PG  - 82-89
LID - S1499-2671(16)30134-4 [pii]
LID - 10.1016/j.jcjd.2016.07.007 [doi]
AB  - OBJECTIVES: The present study aimed to evaluate the role of hyperlipidemia in 
      increased formation of advanced lipoxidation end products (ALEs) and to evaluate 
      whether there is any relationship between ALEs generation and erythrocyte 
      glucose-6-phosphate dehydrogenase (G6PD) activity in cases of mild 
      nonproliferative diabetic retinopathy (MNPDR). METHODS: In this study, we 
      enrolled 100 patients with type 2 diabetes and MNPDR, 100 subjects with type 2 
      diabetes but without retinopathy (DNR) and 90 normal individuals without diabetes 
      as healthy controls (HCs). Erythrocyte nicotinamide dinucleotide phosphate 
      (NADPH), G6PD activity, serum total cholesterol, low- and high-density 
      lipoprotein (LDL, HDL) and triglyceride levels were determined by photometric 
      assay. Serum malondialdehyde (MDA) protein adduct and hexanoyl-lysine (HEL) were 
      measured by an enzyme-linked immunosorbent assay (ELISA). RESULTS: A robust 
      linear relationship was observed between MDA protein adduct and LDL or 
      cholesterol or triglyceride levels, and HEL and LDL or cholesterol or 
      triglyceride levels in subjects with MNPDR (p=0.0001). A significant inverse 
      association was observed between erythrocyte G6PD activity and serum MDA protein 
      adductor HEL levels in subjects with MNPDR (p=0.0001). CONCLUSIONS: 
      Hyperlipidemia is an important factor that is associated with increased ALEs 
      formation in persons with MNPDR. Increased ALEs generation was associated with 
      decreased G6PD activity and low NADPH levels in cases of MNPDR, suggesting their 
      detrimental role in the occurrence of early NPDR.
CI  - Copyright (c) 2016 Canadian Diabetes Association. Published by Elsevier Inc. All 
      rights reserved.
FAU - Choudhuri, Subhadip
AU  - Choudhuri S
AD  - Department of Biochemistry, Dr. B C Roy Post Graduate Institute of Basic Medical 
      Education and Research, Kolkata, India; Department Laboratory Services, GD 
      Hospital & Diabetes Institute, Kolkata, India. Electronic address: 
      schoudhuri6@gmail.com.
FAU - Roy, Pijush Kanti
AU  - Roy PK
AD  - Department Laboratory Services, GD Hospital & Diabetes Institute, Kolkata, India.
FAU - Mitra, Bhaskar
AU  - Mitra B
AD  - Department of Laboratory Services, Drs. Tribedi and Roy Lab, Kolkata, India.
FAU - Sen, Susruta
AU  - Sen S
AD  - Calcutta Medical Research Institute, Kolkata, India.
FAU - Sarkar, Rajarshi
AU  - Sarkar R
AD  - Department Laboratory Services, GD Hospital & Diabetes Institute, Kolkata, India.
FAU - Das, Mandrita
AU  - Das M
AD  - Department Laboratory Services, GD Hospital & Diabetes Institute, Kolkata, India.
FAU - Biswas, Debashree
AU  - Biswas D
AD  - Department of Biochemistry, Dr. B C Roy Post Graduate Institute of Basic Medical 
      Education and Research, Kolkata, India.
FAU - Ghosh, Prithwijit
AU  - Ghosh P
AD  - Department Laboratory Services, GD Hospital & Diabetes Institute, Kolkata, India.
FAU - Biswas, Ajoy
AU  - Biswas A
AD  - Department Laboratory Services, GD Hospital & Diabetes Institute, Kolkata, India.
FAU - Chakraborty, Shaibal
AU  - Chakraborty S
AD  - Department Laboratory Services, GD Hospital & Diabetes Institute, Kolkata, India.
FAU - Mondal, Lakshmi Kanta
AU  - Mondal LK
AD  - Regional Institute of Ophthalmology, Kolkata, India.
LA  - eng
PT  - Journal Article
DEP - 20161201
PL  - Canada
TA  - Can J Diabetes
JT  - Canadian journal of diabetes
JID - 101148810
RN  - 0 (Advanced Oxidation Protein Products)
RN  - 0 (Biomarkers)
RN  - EC 1.1.1.49 (Glucosephosphate Dehydrogenase)
SB  - IM
MH  - Adult
MH  - Advanced Oxidation Protein Products/*blood
MH  - Biomarkers/blood
MH  - Diabetes Mellitus, Type 2/*blood/diagnosis/epidemiology
MH  - Diabetic Retinopathy/*blood/diagnosis/epidemiology
MH  - Erythrocytes/*metabolism
MH  - Female
MH  - Glucosephosphate Dehydrogenase/*blood
MH  - Humans
MH  - Hyperlipidemias/*blood/diagnosis/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Oxidation-Reduction
OTO - NOTNLM
OT  - advanced lipoxidation end products (ALEs)
OT  - diabetic retinopathy
OT  - glucose-6-phosphate dehydrogenase (G6PD)
OT  - glucose-6-phosphate-deshydrogenase (G6PD)
OT  - hyperlipidemia
OT  - hyperlipidemie
OT  - mild nonproliferative diabetic retinopathy (MNPDR)
OT  - nicotinamide-adenine-dinucleotide phosphate reduit (NADPH)
OT  - produits finaux de la lipoxidation avancee (ALE pour advanced lipoxidation end 
      products)
OT  - reduced nicotinamide adenine di nucleotide phosphate (NADPH)
OT  - retinopathie diabetique
OT  - retinopathie diabetique non proliferante minime (RDNP minime)
EDAT- 2016/12/06 06:00
MHDA- 2017/02/10 06:00
CRDT- 2016/12/06 06:00
PHST- 2016/05/08 00:00 [received]
PHST- 2016/06/16 00:00 [revised]
PHST- 2016/07/25 00:00 [accepted]
PHST- 2016/12/06 06:00 [pubmed]
PHST- 2017/02/10 06:00 [medline]
PHST- 2016/12/06 06:00 [entrez]
AID - S1499-2671(16)30134-4 [pii]
AID - 10.1016/j.jcjd.2016.07.007 [doi]
PST - ppublish
SO  - Can J Diabetes. 2017 Feb;41(1):82-89. doi: 10.1016/j.jcjd.2016.07.007. Epub 2016 
      Dec 1.